Literature DB >> 16437604

Anti-Saccharomyces cerevisiae antibody titers are stable over time in Crohn's patients and are not inducible in murine models of colitis.

Stefan Müller1, Maya Styner, Beatrice Seibold-Schmid, Beatrice Flogerzi, Michael Mähler, Astrid Konrad, Frank Seibold.   

Abstract

AIM: To investigate ASCA production over time in CD and murine colitis in order to further our understanding of their etiology.
MATERIALS AND METHODS: Sixty-six CD patients were compared to ulcerative colitis (UC) and irritable bowel syndrome patients with respect to ASCA production as measured by ELISA. ASCA IgG or IgA positivity as well as change in titers over a period of up to 3 years (Delta IgG/A) was correlated with clinical parameters such as CD activity index (CDAI) and C-reactive protein levels (CRP). Moreover, two murine models of colitis (DSS and IL-10 knock out) were compared to control animals with respect to ASCA titers after oral yeast exposure.
RESULTS: ASCA IgG and IgA titers are stable over time in CD and non-CD patients. Fistular disease was associated with a higher rate of ASCA IgA positivity (P = 0.014). Ileal disease was found to have a significant influence on the Delta IgG of ASCA (P = 0.032). There was no correlation found between ASCA positivity or Delta IgG/A and clinical parameters of CD: CDAI and CRP. In mice, neither healthy animals nor animals with DSS-induced or spontaneous colitis exhibited a marked increase in ASCA titers after high-dose yeast exposure. On the other hand, mice immunized intraperitoneally with mannan plus adjuvant showed a marked and significant increase in ASCA titers compared to adjuvant-only immunized controls (P = 0.014).
CONCLUSION: The propensity to produce ASCA in a subgroup of CD patients is largely genetically predetermined as evidenced by their stability and lack of correlation with clinical disease activity parameters. Furthermore, in animal models of colitis, mere oral exposure of mice to yeast does not lead to the induction of marked ASCA titers irrespective of concomitant colonic inflammation. Hence, environment may play only a minor role in inducing ASCA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437604      PMCID: PMC4717042          DOI: 10.3748/wjg.v11.i44.6988

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  The road to Rome.

Authors:  W G Thompson
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

Authors:  S Vermeire; M Peeters; R Vlietinck; S Joossens; E Den Hond; V Bulteel; X Bossuyt; B Geypens; P Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2001-02       Impact factor: 5.325

3.  Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease.

Authors:  W J Sandborn; E V Loftus; J F Colombel; K A Fleming; F Seibold; H A Homburger; B Sendid; R W Chapman; W J Tremaine; D K Kaul; J Wallace; W S Harmsen; A R Zinsmeister; S R Targan
Journal:  Inflamm Bowel Dis       Date:  2001-08       Impact factor: 5.325

4.  Antibody (IgG, IgA, and IgM) to baker's yeast (Saccharomyces cerevisiae), yeast mannan, gliadin, ovalbumin and betalactoglobulin in monozygotic twins with inflammatory bowel disease.

Authors:  E Lindberg; K E Magnusson; C Tysk; G Järnerot
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

5.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup.

Authors:  E A Vasiliauskas; S E Plevy; C J Landers; S W Binder; D M Ferguson; H Yang; J I Rotter; A Vidrich; S R Targan
Journal:  Gastroenterology       Date:  1996-06       Impact factor: 22.682

6.  Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease.

Authors:  H McKenzie; J Main; C R Pennington; D Parratt
Journal:  Gut       Date:  1990-05       Impact factor: 23.059

7.  Specific antibody response to oligomannosidic epitopes in Crohn's disease.

Authors:  B Sendid; J F Colombel; P M Jacquinot; C Faille; J Fruit; A Cortot; D Lucidarme; D Camus; D Poulain
Journal:  Clin Diagn Lab Immunol       Date:  1996-03

8.  Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease.

Authors:  B Sendid; J F Quinton; G Charrier; O Goulet; A Cortot; B Grandbastien; D Poulain; J F Colombel
Journal:  Am J Gastroenterol       Date:  1998-08       Impact factor: 10.864

9.  Method for fingerprinting yeast cell wall mannans.

Authors:  J Kocourek; C E Ballou
Journal:  J Bacteriol       Date:  1969-12       Impact factor: 3.490

10.  Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease.

Authors:  J Main; H McKenzie; G R Yeaman; M A Kerr; D Robson; C R Pennington; D Parratt
Journal:  BMJ       Date:  1988-10-29
View more
  1 in total

1.  Inflammatory bowel disease serology in Asia and the West.

Authors:  Lani Prideaux; Michael A Kamm; Peter De Cruz; Daniel R van Langenberg; Siew C Ng; Iris Dotan
Journal:  World J Gastroenterol       Date:  2013-10-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.